Download PDF
Klin Monbl Augenheilkd 2012; 229(4): 451-453
DOI: 10.1055/s-0031-1299207
Der interessante Fall
© Georg Thieme Verlag KG Stuttgart · New York

Intravitreal Administration of Ranibizumab for Idiopathic Choroidal Neovascularization in a Pregnant Woman

Intravitreale Verabreichung von Ranibizumab zur Therapie der idiopathischen choroidalen Neovaskularisation bei einer schwangeren Frau
A. Sarhianaki
1   Department of Obstetrics and Gynaecology, General Hospital of Patras “Agios Andreas”, Patras, Greece
,
A. Katsimpris
2   Department of Ophthalmology, General Hospital of Patras “Agios Andreas”, Patras, Greece
,
I. K. Petropoulos
3   Ophthalmological Centre of Rive, Geneva, Switzerland
,
A. Livieratou
2   Department of Ophthalmology, General Hospital of Patras “Agios Andreas”, Patras, Greece
,
P. E. Theoulakis
4   Moorfields Eye Hospital NHS Foundation Trust, London, United Kingdom
,
J. M. Katsimpris
2   Department of Ophthalmology, General Hospital of Patras “Agios Andreas”, Patras, Greece
› Author Affiliations
Further Information

Publication History

Publication Date:
11 April 2012 (online)

Also available at
    Permissions and Reprints

Introduction

Idiopathic choroidal neovascularization (ICNV) is a rare form of choroidal neovascularization (CNV) affecting patients of working age (age ≤ 50 years) and having a significant impact on visual acuity (VA) and quality of life [1]. The occurrence of ICNV in pregnancy is very rare and has been reported in the literature only twice [2] [3]. Treatment of ICNV with ranibizumab and bevacizumab has been reported in small case series [3] [4] [5].

We report a case of subfoveal ICNV and its treatment with intravitreal ranibizumab in a healthy, young woman during the third trimester of pregnancy.

 

  • References

  • 1 Lindblom B, Andersson T. The prognosis of idiopathic choroidal neovascularization in persons younger than 50 years of age. Ophthalmology 1998; 105: 1816-1820
    CrossrefPubMedGoogle Scholar
  • 2 Rhee P, Dev S, Mieler WF. The development of choroidal neovascularization in pregnancy. Retina 1999; 19: 520-524
    CrossrefPubMedGoogle Scholar
  • 3 Anastasilakis K, Symeonidis C, Kaprinis K et al. Peripapillary neovascular membrane in a young pregnant woman and prompt response to ranibizumab injections following uneventful delivery. Case Report. Ophthalmol 2011; 2: 129-133
    PubMedGoogle Scholar
  • 4 Mandal S, Garg S, Venkatesh P et al. Intravitreal bevacizumab for subfoveal idiopathic choroidal neovascularization. Arch Ophthalmol 2007; 125: 1487-1492
    CrossrefPubMedGoogle Scholar
  • 5 Chan WM, Lai TY, Liu DT et al. Intravitreal bevacizumab (avastin) for choroidal neovascularization secondary to central serous chorioretinopathy, secondary to punctate inner choroidopathy, or of idiopathic origin. Am J Ophthalmol 2007; 143: 977-983
    CrossrefPubMedGoogle Scholar
  • 6 Sim DA, Sheth HG, Kaines A et al. Punctate inner choroidopathy-associated choroidal neovascular membranes during pregnancy. Eye 2008; 22: 725-727
    CrossrefPubMedGoogle Scholar
  • 7 Vuorela P, Hatva E, Lymboussaki A et al. Expression of vascular endothelial growth factor and placenta growth factor in human placenta. Biol Reprod 1997; 56: 489-494
    CrossrefPubMedGoogle Scholar
  • 8 US Food and Drug Administration. LUCENTISTM (ranibizumab injection). 2006 http://www.accessdata.fda.gov/drugsatfda_docs/label/2006/125156lbl.pdf (accessed 5th November 2011).
    PubMedGoogle Scholar
  • 9 Friberg TR. Ranibizumab-pegaptanib therapy for idiopathic choroidal neovascularization: report of a case. Semin Ophthalmol 2007; 22: 137-139
    CrossrefPubMedGoogle Scholar